Andrew J. Einhorn's most recent trade in RVL Pharmaceuticals plc was a trade of 9,607 Ordinary Shares done at an average price of $1.1 . Disclosure was reported to the exchange on Jan. 24, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| RVL Pharmaceuticals plc | Andrew J. Einhorn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.13 per share. | 24 Jan 2022 | 9,607 | 141,473 (0%) | 0% | 1.1 | 10,856 | Ordinary Shares |
| RVL Pharmaceuticals plc | Andrew J. Einhorn | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2021 | 249,814 | 249,814 | - | - | Share Option (Right to Buy) | |
| RVL Pharmaceuticals plc | Andrew J. Einhorn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.12 per share. | 18 May 2021 | 6,467 | 151,080 (0%) | 0% | 3.1 | 20,177 | Ordinary Shares |
| RVL Pharmaceuticals plc | Andrew J. Einhorn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.46 per share. | 24 Jan 2021 | 9,668 | 157,547 (0%) | 0% | 4.5 | 43,119 | Ordinary Shares |